Heightened BMI, significant weight loss goals, type 2 diabetes or prediabetes, and patients who want the most effective pharmaceutical weight loss option currently available, supported by clinical monitoring
Tirzepatide is a novel glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist licensed in the UK for the treatment of type 2 diabetes mellitus (as Mounjaro) and, more recently, for chronic weight management in adults with obesity or overweight with weight-related comorbidities (as Zepbound)
In the past, only select GLP-1 medications were covered by Medicare Part D (the programs prescription medication benefit) to help treat type 2 diabetes and cardiovascular disease
all mechanistic data on BPC-157 are derived exclusively from preclinical and in vitro studies
Current research is still trying to determine how it can help with age-related diseases such as osteoarthritis and brain diseases (6)
[2] State licensure alone does not guarantee formulation quality